Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas
Journal of Clinical Oncology · 10.10.2026 · 44 (29) · 2811-2823
DOI: 10.1200/jco-25-01846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2026. Verfasst von Connor J Kinslow und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era. METHODS The Prospective Gliomas Research (PROGRES) database contains individual patient-level data from 11 prospective clinical trials or observational registries of histologically defined lower-grade 2-3 oligodendroglioma or astrocytoma. We determined the association of age (18-39 years v ≥40 years) with progression-free survival (PFS) stratified by isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) status, using log-rank tests and Cox regression models. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] database). RESULTS We identified 1,619 and 1,292 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH -wildtype tumors were more common in patients 40 years and older (38% v 5%, odds ratio: 11.3 [95% CI, 6.5 to 19.7]). Age was associated with PFS in IDH -wildtype (5-year PFS for ≥40 v 18-39 years: 6% v 24%, hazard ratio [HR], 1.74 [95% CI, 1.21 to 2.50]) but not in IDH -mutant glioma (60% v 59%, HR, 0.89 [95% CI, 0.76 to 1.05], P interaction < .001). In IDH -wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% v 28%), EGFR amplification (41% v 15%), and chromosome +7/–10 alteration (57% v 25%). In a pooled analysis of four clinical trials, age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone for IDH -mutant glioma. CONCLUSION In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral of adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York, NY.
- Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York, NY.
- IRCCS Neuromed, Pozzilli, Isernia, Italy.
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
- Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
ORCID-Profile: Connor J Kinslow, Paul D Brown, Michael A Vogelbaum, Karla V Ballman, Ann Mercurio, Kyle Tuohy, Alireza Mansouri, Mehdi Touat, Caroline Dehais, Angelo Dipasquale, Jack Grinband, James B Yu, Henry Walch, Mitchell I Parker, Igor Shuryak, Soumyajit Roy, Matthew Gallitto, David P Horowitz, Guy M McKhann, Jeffrey N Bruce, Quinn T Ostrom, Alfred I Neugut, Luke R G Pike, Simon K Cheng, Lisa A Kachnic, Minesh P Mehta, Tony J C Wang
Zitieren
APA
Kinslow, C. J., Minniti, G., Brown, P. D., Vogelbaum, M. A., Ballman, K. V., Mercurio, A., Siegelin, M. D., Kocakavuk, E., Tuohy, K., Mansouri, A., Touat, M., Ducray, F., Dehais, C., Dipasquale, A., Simonelli, M., DeStephano, D. M., Grinband, J., Yu, J. B., Walch, H., …, & Wang, T. J. C. (2026). Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas. Journal of Clinical Oncology, 44(29), 2811-2823. https://doi.org/10.1200/jco-25-01846
Vancouver
Kinslow CJ, Minniti G, Brown PD, Vogelbaum MA, Ballman KV, Mercurio A, et al. Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas. Journal of Clinical Oncology. 2026;44(29):2811-2823. doi:10.1200/jco-25-01846
BibTeX
@article{Kinslow2026,
author = {Kinslow, Connor J and Minniti, Giuseppe and Brown, Paul D and Vogelbaum, Michael A and Ballman, Karla V and Mercurio, Ann and Siegelin, Markus D and Kocakavuk, Emre and Tuohy, Kyle and Mansouri, Alireza and Touat, Mehdi and Ducray, François and Dehais, Caroline and Dipasquale, Angelo and Simonelli, Matteo and DeStephano, David M and Grinband, Jack and Yu, James B and Walch, Henry and Parker, Mitchell I and Shuryak, Igor and Roy, Soumyajit and Hervey-Jumper, Shawn L and Gallitto, Matthew and Horowitz, David P and McKhann, Guy M and Sisti, Michael B and Bruce, Jeffrey N and Canoll, Peter and Ostrom, Quinn T and Neugut, Alfred I and Pike, Luke R G and Iwamoto, Fabio M and Cheng, Simon K and Kachnic, Lisa A and Mehta, Minesh P and Wang, Tony J C},
title = {Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {29},
pages = {2811--2823},
doi = {10.1200/jco-25-01846}
}
EUVIMED